HRP20000866B1 - A reference compound for use in the analysis of levosimendan batches - Google Patents

A reference compound for use in the analysis of levosimendan batches

Info

Publication number
HRP20000866B1
HRP20000866B1 HR20000866A HRP20000866A HRP20000866B1 HR P20000866 B1 HRP20000866 B1 HR P20000866B1 HR 20000866 A HR20000866 A HR 20000866A HR P20000866 A HRP20000866 A HR P20000866A HR P20000866 B1 HRP20000866 B1 HR P20000866B1
Authority
HR
Croatia
Prior art keywords
analysis
reference compound
levosimendan
batches
levosimendan batches
Prior art date
Application number
HR20000866A
Other languages
English (en)
Croatian (hr)
Inventor
Baeckstroem Reijo
Heinonen Tuula
Hauta-Aho Tuula
Original Assignee
Orion Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corporation filed Critical Orion Corporation
Publication of HRP20000866A2 publication Critical patent/HRP20000866A2/hr
Publication of HRP20000866B1 publication Critical patent/HRP20000866B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32Oxygen atoms
    • C07D307/33Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/04Preparation or injection of sample to be analysed
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/04Preparation or injection of sample to be analysed
    • G01N2030/042Standards
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/14Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222Hetero-O [e.g., ascorbic acid, etc.]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/14Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555Hetero-N
    • Y10T436/147777Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HR20000866A 1998-06-18 2000-12-15 A reference compound for use in the analysis of levosimendan batches HRP20000866B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI981428A FI104718B (fi) 1998-06-18 1998-06-18 [[4-(2-atsido-3-metyyli-5-oksotetrahydrofuran-2-yyli)fenyyli]hydratsono]propaanidinitriili käytettäväksi referenssiaineena levosimendaanierien analyysissä
PCT/FI1999/000539 WO1999065888A2 (en) 1998-06-18 1999-06-18 A reference compound for use in the analysis of levosimendan batches

Publications (2)

Publication Number Publication Date
HRP20000866A2 HRP20000866A2 (en) 2001-12-31
HRP20000866B1 true HRP20000866B1 (en) 2009-02-28

Family

ID=8552039

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20000866A HRP20000866B1 (en) 1998-06-18 2000-12-15 A reference compound for use in the analysis of levosimendan batches

Country Status (28)

Country Link
US (1) US6340764B1 (xx)
EP (1) EP1087956B1 (xx)
JP (1) JP4550279B2 (xx)
KR (1) KR100661772B1 (xx)
CN (1) CN1129590C (xx)
AR (1) AR018879A1 (xx)
AT (1) ATE253566T1 (xx)
AU (1) AU755699B2 (xx)
BR (1) BR9911230A (xx)
CA (1) CA2334864C (xx)
CZ (1) CZ298659B6 (xx)
DE (1) DE69912604D1 (xx)
EA (1) EA002854B1 (xx)
ES (1) ES2211113T3 (xx)
FI (1) FI104718B (xx)
HK (1) HK1032779A1 (xx)
HR (1) HRP20000866B1 (xx)
HU (1) HU229582B1 (xx)
ID (1) ID29239A (xx)
IL (1) IL139964A (xx)
MX (1) MXPA00012436A (xx)
NO (1) NO325393B1 (xx)
NZ (1) NZ508557A (xx)
PL (1) PL201772B1 (xx)
RS (1) RS49929B (xx)
SK (1) SK284353B6 (xx)
WO (1) WO1999065888A2 (xx)
ZA (1) ZA200006993B (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2563776A1 (en) 2004-04-21 2005-11-10 Teva Pharmaceutical Industries Ltd. Processes for preparing montelukast sodium
FR2877013A1 (fr) * 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
ES2358923T3 (es) 2005-07-05 2011-05-16 Teva Pharmaceutical Industries, Ltd. Purificación de montelukast.
CN104230816B (zh) * 2014-09-19 2017-02-15 成都新恒创药业有限公司 一种左西孟旦潜在基因毒性杂质及其制备、检测方法
CN104478809B (zh) * 2014-11-14 2016-08-17 成都新恒创药业有限公司 一种左西孟旦杂质及其制备和检测方法
CN105817632A (zh) * 2015-01-09 2016-08-03 中国科学院宁波材料技术与工程研究所 片状粉末的制备装置及方法
CN105784895B (zh) * 2015-10-30 2018-05-22 成都欣捷高新技术开发有限公司 一种用高效液相色谱仪检测左西孟旦中杂质的方法
CN111474289A (zh) * 2019-10-31 2020-07-31 武汉嘉诺康医药技术有限公司 一种利用反相色谱分离分析左西孟旦中右西孟旦的方法
CA3161960A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0359439A1 (en) * 1988-09-07 1990-03-21 Orion-Yhtymä Oy Substituted pyridazinones
EP0383449A2 (en) * 1989-02-11 1990-08-22 Orion-Yhtymà„ Oy Pyridazinone derivatives and processes for preparing the same
WO1997035841A2 (en) * 1996-03-27 1997-10-02 Orion-Yhtymä Oy Method for obtaining pure enantiomers of a pyridazinone derivative

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB383449A (en) * 1931-12-12 1932-11-17 Percy Charles Barton Improvements relating to masts, poles, or like supports and their manufacture
GB565546A (en) * 1943-04-13 1944-11-15 Leslie Frederick Reeve A pneumatically operated pickup unit for use in electric organs and the like
GB2251615B (en) * 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
GB2266841A (en) * 1992-05-06 1993-11-17 Orion Yhtymae Oy Compounds for use as anti-ischemic medicaments
GB9614098D0 (en) * 1996-07-05 1996-09-04 Orion Yhtymae Oy Transdermal delivery of levosimendan
GB9915179D0 (en) * 1999-06-29 1999-09-01 Orion Corp A method for the treatment or prevention of coronary graft vasospasm

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0359439A1 (en) * 1988-09-07 1990-03-21 Orion-Yhtymä Oy Substituted pyridazinones
EP0383449A2 (en) * 1989-02-11 1990-08-22 Orion-Yhtymà„ Oy Pyridazinone derivatives and processes for preparing the same
WO1997035841A2 (en) * 1996-03-27 1997-10-02 Orion-Yhtymä Oy Method for obtaining pure enantiomers of a pyridazinone derivative

Also Published As

Publication number Publication date
NZ508557A (en) 2002-05-31
PL201772B1 (pl) 2009-05-29
BR9911230A (pt) 2001-03-06
JP2002518383A (ja) 2002-06-25
ZA200006993B (en) 2002-02-28
CZ20004555A3 (en) 2001-05-16
NO325393B1 (no) 2008-04-21
IL139964A (en) 2003-07-06
MXPA00012436A (es) 2002-06-04
NO20006444D0 (no) 2000-12-15
HU229582B1 (en) 2014-02-28
KR20010072622A (ko) 2001-07-31
NO20006444L (no) 2000-12-15
AR018879A1 (es) 2001-12-12
HK1032779A1 (en) 2001-08-03
SK18722000A3 (sk) 2001-09-11
ATE253566T1 (de) 2003-11-15
FI981428A (fi) 1999-12-19
FI104718B (fi) 2000-03-31
EA002854B1 (ru) 2002-10-31
ES2211113T3 (es) 2004-07-01
YU76700A (sh) 2002-11-15
CA2334864C (en) 2008-01-15
IL139964A0 (en) 2002-02-10
WO1999065888A3 (en) 2000-01-27
EA200100055A1 (ru) 2001-06-25
EP1087956A2 (en) 2001-04-04
WO1999065888A2 (en) 1999-12-23
SK284353B6 (sk) 2005-02-04
DE69912604D1 (de) 2003-12-11
AU755699B2 (en) 2002-12-19
CA2334864A1 (en) 1999-12-23
CN1129590C (zh) 2003-12-03
HUP0102020A3 (en) 2002-04-29
JP4550279B2 (ja) 2010-09-22
US6340764B1 (en) 2002-01-22
AU4786399A (en) 2000-01-05
HUP0102020A2 (hu) 2001-12-28
FI981428A0 (fi) 1998-06-18
PL347577A1 (en) 2002-04-08
CN1306527A (zh) 2001-08-01
ID29239A (id) 2001-08-16
HRP20000866A2 (en) 2001-12-31
CZ298659B6 (cs) 2007-12-12
RS49929B (sr) 2008-09-29
EP1087956B1 (en) 2003-11-05
KR100661772B1 (ko) 2006-12-28

Similar Documents

Publication Publication Date Title
IS4963A (is) Setnar 6,5-heteró-bísýklískar afleiður
FI916165A0 (fi) 1,3-oxatiolannukleosidanaloger.
ID18189A (id) Dervat-derivat 6,6-hetero-bisiklik yang disubstitusi
TR199501656A2 (tr) Kimyasal bilesenler.
DE59501320D1 (de) Ketotricyclo(5.2.1.0.)decan-Derivate
MA24139A1 (fr) Alkylsulfates .
TR199700049A2 (tr) Düsük CO'lu sigara.
FI902190A0 (fi) Anordning foer framstaellning av heta drycker i en mikrovaogsugn.
DE69205568D1 (de) Turbinengehaeuse.
TR28098A (tr) 1,2,4-okzadiazol türevleri.
MA23778A1 (fr) Purine-6-ones-2,9 disubstituees
TR27961A (tr) Sübstitüe edilmis 1,2,3,4 -tetrahidro-5-nitro-pirimidinler.
KR970002468A (ko) 화학증폭형 포지티브 레지스트 조성물
ITTO910599A0 (it) Amplificatore,particolarmente amplificatore integrato.
TR199802520A3 (tr) 1,3,8-Triaza-spiro(4,5) dekan -4-on türevleri.
DE69003121D1 (de) Filmbildendes Mittel.
HRP20000866B1 (en) A reference compound for use in the analysis of levosimendan batches
DE69427286D1 (de) 7,42-bis (o-demethyl)rapamycin
DE69107150D1 (de) 1,1,1-Trishdroxyphenyläthanacrylate.
FI910384A0 (fi) Drivanordning till en roerformig vals.
IT238704Y1 (it) Cassetto.
DE69107742D1 (de) Substituierte 3,7,9-Trioxa-1-aza-2,8-diphosphaspiro[4.5]dekane und stabilisierte Zusammensetzungen.
KR920000835U (ko) 화장실 등에 사용되는 부스 (Booth)
TR199700219A3 (tr) 1,25-Dihidroksi-16, 22, 23-Trisdihidro-kolkalsiferol türevleri.
TR199701011A2 (xx) 1-karba-(detia)-sefalosforin t�revleri.

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20180604

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20190618